China Renaissance Adjusts Price Target on Microsoft to $520 From $470, Maintains Buy Rating
Visa Analyst Ratings
Maintaining Hold on Visa: Assessing Slowing Growth and Competitive Pressures
Analysts Offer Insights on Financial Companies: Chubb (CB), MSCI (MSCI) and Visa (V)
Goldman Sachs Remains a Buy on Visa (V)
TD Cowen Maintains Visa(V.US) With Buy Rating, Cuts Target Price to $318
KBW Maintains Visa(V.US) With Buy Rating, Maintains Target Price $325
KBW Reaffirms Their Buy Rating on Visa (V)
Visa Maintains Buy Rating Amid Consistent Performance and Growth Prospects
Cantor Fitzgerald Maintains UnitedHealth(UNH.US) With Buy Rating, Maintains Target Price $591
UnitedHealth Group Analyst Ratings
Redburn Atlantic Adjusts Price Target on Goldman Sachs to $450 From $400
TD Cowen Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $360
Piper Sandler Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $344
Microsoft Analyst Ratings
Microsoft Remains a Strong Buy; Azure, AI Momentum Overshadows Outage Panic
Morgan Stanley Adjusts Price Target on Visa to $326 From $318, Maintains Overweight Rating
BNP Paribas Exane Adjusts Price Target on Microsoft to $525 From $495, Maintains Outperform Rating
Buy Rating on UnitedHealth Group: Proactive Management and Strong Growth Outlook
BNP Paribas Exane Adjusts Price Target on Goldman Sachs to $485 From $415, Maintains Neutral Rating